We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
-21.9%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.8B
AUM Growth
-$63.5M
Cap. Flow
+$448M
Cap. Flow %
24.92%
Top 10 Hldgs %
55.9%
Holding
105
New
11
Increased
30
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$58.4M
2
NVRO
NEVRO CORP.
NVRO
+$57.5M
3
CSII
Cardiovascular Systems, Inc.
CSII
+$30.2M
4
HTWR
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
+$18.2M
5
MASI
Masimo
MASI
+$17.2M

Top Sells

Rank Stock Value
1
ASRT
Assertio
ASRT
+$25.1M
2
ALR
Alere Inc
ALR
+$23.9M
3
HRTX icon
Heron Therapeutics
HRTX
+$17.8M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$12.8M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 63.28%
2 Technology 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYNA
51
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$9.05M 0.5%
586,117
-292,000
-33% -$4.74M
ATRC icon
52
AtriCure
ATRC
$1.77B
$8.84M 0.49%
403,519
-79,835
-17% -$2M
RPTP
53
DELISTED
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
$8.55M 0.48%
1,412,995
+93,112
+7% +$1.14M
ADMA icon
54
ADMA Biologics
ADMA
$1.92B
$8.06M 0.45%
964,193
– –
AMRN
55
Amarin Corp
AMRN
$284M
$8.06M 0.45%
208,761
+32,500
+18% +$1.47M
ELOS
56
DELISTED
Syneron Medical Ltd
ELOS
$7.54M 0.42%
1,055,221
+50,000
+5% +$480K
GNCA
57
DELISTED
Genocea Biosciences, Inc.
GNCA
$7.17M 0.4%
130,780
+6,185
+5% +$613K
ANTH
58
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$7.03M 0.39%
144,334
-26,973
-16% -$1.88M
VXRT
59
DELISTED
Vaxart
VXRT
$6.9M 0.38%
316,974
+79,546
+34% +$1.93M
PLXP
60
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$6.52M 0.36%
58,247
-1,128
-2% -$130K
CFRX
61
DELISTED
ContraFect Corporation
CFRX
$6.31M 0.35%
1,773
– –
FATE icon
62
Fate Therapeutics
FATE
$281M
$5.94M 0.33%
1,113,986
-186,014
-14% -$1.27M
TENX icon
63
Tenax Therapeutics
TENX
$385M
$5.91M 0.33%
62
– –
SCYX icon
64
SCYNEXIS
SCYX
$37M
$5.64M 0.31%
9,688
– –
IRMD icon
65
iRadimed
IRMD
$1.21B
$5.61M 0.31%
230,358
-125,326
-35% -$3M
BLRX
66
BioLineRX
BLRX
$12.3M
$5.36M 0.3%
5,833
+666
+13% +$711K
FLXN
67
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4.8M 0.27%
323,188
-25,016
-7% -$587K
TNXP icon
68
Tonix Pharmaceuticals
TNXP
$157M
– –
0
– –
KALV
69
DELISTED
KalVista Pharmaceuticals
KALV
$4.21M 0.23%
84,210
– –
MDWD icon
70
MediWound
MDWD
$183M
$3.89M 0.22%
72,796
+55,672
+325% +$2.74M
ARAY icon
71
Accuray
ARAY
$28.4M
$3.75M 0.21%
750,000
-250,000
-25% -$1.61M
VCYT icon
72
Veracyte
VCYT
$4.52B
$3.45M 0.19%
736,196
– –
EPRS
73
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$3.43M 0.19%
775,000
– –
CASM
74
DELISTED
CAS Medical Systems, Inc.
CASM
$3.27M 0.18%
2,618,296
– –
OSUR icon
75
OraSure Technologies
OSUR
$273M
$3.04M 0.17%
685,528
– –
1 2
3
4 5

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2015 Portfolio in Review

As of Q3 2015, Broadfin Capital held 105 positions worth $1.8B, down 3.4% from $1.86B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Broadfin Capital deployed $448M of net new capital in Q3 2015, opening 11 new positions and adding to 30 existing holdings. Its largest new stake was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 76% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Heron Therapeutics, an estimated $17.8M trimmed.

  • Broadfin Capital's largest Q3 2015 buy was Cardiovascular Systems, Inc.: 1,200,000 shares worth $19M.
  • Broadfin Capital added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2015, an estimated $58.4M increase.
  • Broadfin Capital's biggest Q3 2015 reduction was Heron Therapeutics, cutting an estimated $17.8M.
  • Broadfin Capital fully exited Assertio in Q3 2015, selling an estimated $25.1M.
  • Broadfin Capital's ten largest holdings make up 56% of its $1.8B portfolio in Q3 2015.
  • Broadfin Capital opened 11 new positions and closed 15 in Q3 2015.
  • Broadfin Capital's portfolio value fell 3.4% quarter-over-quarter to $1.8B.

Based on Broadfin Capital's 13F filing for Q3 2015, filed 16 Nov 2015.